022dc727 C077 4611 8a3d 967ee99f9828 01
Topiramate
Product Images NDC 70934-450
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 70934-450). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
022dc727 C077 4611 8a3d 967ee99f9828 02
This is a graph displaying the cumulative rates for the time to the first seizure for patients taking Topiramate at a dosage of 50mg/day (N=234) and 400mg/day (N=236). The x-axis shows the time in days and the y-axis shows the cumulative rates. There is no further information available.*
022dc727 C077 4611 8a3d 967ee99f9828 03
During the Double-Blind Phase, there was a significant decrease in the average monthly migraine period rate of 56% compared to the baseline. This change was observed in patients taking both 100 and 200 milligrams of Topamax per day. The results are statistically significant with *p<0.010 and **p<0.001.*
70934 450 30 Master Bottle Label Approval Rev A 10 19
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
